Antimicrobial susceptibilities of Francisella tularensis subsp. holarctica strains isolated from humans in the Central Anatolia region of Turkey

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 11, 2011, Pages 2588-2592

  Yeşilyurt, Murat ^a   Kiliç, Selçuk ^b   Çelebi, Bekir ^b   Çelik, Mesure ^c   Gül, Serdar ^a   Erdoǧan, Fikret ^d   Özel, Gönül ^c  

^a Sorgun Devlet Hastanesi   (Turkey)

^b Refik Saydam National Public Health Agency   (Turkey)

^c Yozgat State Hospital   (Turkey)

^d Provincial Health Directorate   (Turkey)

Author keywords

Antimicrobial susceptibility; Etest; MIC; Tularaemia

Indexed keywords

AGAR; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFEPIME; CEFOPERAZONE; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; CYSTEINE; ERYTHROMYCIN; GENTAMICIN; GLUCOSE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; DRUG EFFICACY; EPSILOMETER TEST; FRANCISELLA; FRANCISELLA TULARENSIS HOLARCTICA; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TULAREMIA; TURKEY (REPUBLIC);

ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; DISEASE OUTBREAKS; FRANCISELLA TULARENSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; TULAREMIA; TURKEY;

EID: 80054698084     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr338     Document Type: Article

References (23)

1. WHO. WHO Guidelines on Tularemia. Geneva, Switzerland: WHO, 2007. http://www.cdc.gov/tularemia/resources/whotularemiamanual.pdf.
2. Sjöstedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci 2007; 1105: 1-29.
3. Ellis J, Oyston PC, Gren M et al. Tularemia. Clin Microbiol Rev 2002; 15: 631-46.
4. Tärnvik A, Chu MC. New approaches to diagnosis and therapy of tularemia. Ann N Y Acad Sci 2007; 1105: 378-404.
5. Enderlin G, Morales L, Jacobs RF et al. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994; 19: 42-7.
6. Tomaso H, Al Dahouk S, Hofer E et al. Antimicrobial susceptibilities of Austrian Francisella tularensis holarctica biovar II strains. Int J Antimicrob Agents 2005; 26: 279-84.
7. Sjöstedt A, Kuoppa K, Johansson T et al. The 17 kDa lipoprotein and encoding gene of Francisella tularensis LVS are conserved in strains of Francisella tularensis. Microb Pathog 1992; 13: 243-9.
8. Broekhuijsen M, Larsson P, Johansson A et al. Genome-wide DNA microarray analysis of Francisella tularensis strains demonstrates extensive genetic conservation within the species but identifies regions that are unique to the highly virulent F. tularensis subsp. tularensis. J Clin Microbiol 2003; 7: 2924-31.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
10. Scheel O, Hoel T, Sandvik T et al. Susceptibility pattern of Scandinavian Francisella tularensis isolates with regard to oral and parenteral antimicrobial agents. APMIS 1993; 101: 33-6.
11. Urich SK, Petersen JM. In vitro susceptibility of isolates of Francisella tularensis types A and B from North America. Antimicrob Agents Chemother 2008; 6: 2276-8.
12. Syrjala H, Schildt R, Raisainen S. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis 1991; 10: 68-70.
13. Ikaheimo I, Syrjala H, Karhukorpi J et al. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 2000; 46: 287-90.
14. Johansson A, Sandra KU, May C et al. In vitro susceptibility to quinolones of Francisella tularensis subspecies tularensis. Scand J Infect Dis 2002; 34: 327-30.
15. Valade E, Vaissaire J, Merens A et al. Susceptibility of 71 French isolates of Francisella tularensis subsp. holarctica to eight antibiotics and accuracy of the Etest method. J Antimicrob Chemother 2008; 62: 208-10.
16. García del Blanco N, Gutiérrez Martín CB, de la Puente Redondo VA et al. In vitro susceptibility of field isolates of Francisella tularensis subsp. holarctica recovered in Spain to several antimicrobial agents. Res Vet Sci 2004; 3: 195-8.
17. George AP. Tigecycline. J Antimicrob Chemother 2005; 56: 470-80.
18. Bina XR, Wang C, Miller MA et al. The Bla2 β-lactamase from the live-vaccine strain of Francisella tularensis encodes a functional protein that is only active against penicillin-class β-lactam antibiotics. Arch Microbiol 2006; 186: 219-28.
19. Kudelina RI, Olsufiev NG. Sensitivity to macrolide antibiotics and lincomycin in Francisella tularensis holarctica. J Hyg Epidemiol Microbiol Immunol 1980; 24: 84-91.
20. Alcalá L, Ruiz-Serrano MJ, Pérez-Fernández TC et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 2003; 47: 416-7.
21. Meric M, Willke A, Finke EJ et al. Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia. APMIS 2008; 116: 66-73.
22. Perez-Castrillon JL, Bachiller-Luque P, Martin-Luquero M et al. Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin Infect Dis 2001; 33: 573-6.
23. Johansson A, Berglund L, Gothefors L et al. Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J 2000; 19: 449-53.